BriaCell granted New Zealand patent for cancer immunotherapy method

PHILADELPHIA/VANCOUVER - BriaCell Therapeutics Corp. (NASDAQ:BCTX, TSX:BCT), a micro-cap biotechnology company with a market value of $2.5 million, announced Wednesday it has been granted New Zealand Patent No. 785587 for its whole-cell cancer immunotherapy technology. According to InvestingPro data, analysts anticipate significant sales growth this year, though the company maintains a weak financial health score.

The patent, titled "Whole-Cell Cancer Vaccines and Methods for Selection Thereof," covers methods of selecting immunotherapy for cancer patients based on HLA allele profile matching. The patent provides exclusivity through February 27, 2037.

The technology supports BriaCell’s precision medicine approach that aims to personalize immunotherapy treatments. The patent is part of the company’s strategy to build an international patent portfolio enabling global development of its immunotherapy platform across multiple cancer indications.

"We are thrilled that the New Zealand Patent Office recognized the innovative nature of BriaCell’s novel whole cell immunotherapy and its potential therapeutic applications for cancer patients," said Dr. William V. Williams, President and CEO of BriaCell.

BriaCell Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer treatment. The company’s announcement was based on a press release statement issued by BriaCell.

In other recent news, BriaCell Therapeutics Corp. reported a 52% one-year survival rate in its Phase 2 clinical study of Bria-IMT for metastatic breast cancer, surpassing expectations compared to current standard therapies. The company also announced the addition of two major cancer centers, Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven, to its Phase 3 breast cancer study, expanding the trial to 58 active clinical sites across 15 states. Furthermore, BriaCell’s Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor will continue without modifications after a third consecutive positive safety review by the independent Data Safety Monitoring Board.

In another development, BriaCell has advanced its Bria-OTS immunotherapy to the combination phase with a checkpoint inhibitor in a clinical study for metastatic breast cancer. This follows the successful completion of the safety evaluation phase of Bria-OTS monotherapy, where one patient experienced a complete resolution of lung metastasis. These recent developments indicate ongoing progress in BriaCell’s efforts to enhance cancer treatment options.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.